Beone Medicines earnings were $915.6M for the trailing 12 months ending Sep 30, 2026, with 1,140% growth year over year. The latest ONC earnings report on Sep 30, 2026 announced Q3 2026 earnings of $384.7M, up 62.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ONC reported annual earnings of $286.9M, with -144.5% growth.
ONC past earnings growth
How has ONC's earnings growth performed historically?
What were Beone Medicines's earnings last quarter?
On ONC's earnings call on Nov 5, 2026, Beone Medicines (NASDAQ: ONC) reported Q3 2026 earnings per share (EPS) of $0.26, up 188.89% year over year. Total ONC earnings for the quarter were $384.71 million. In the same quarter last year, Beone Medicines's earnings per share (EPS) was $0.09.
As of the last Beone Medicines earnings report, Beone Medicines is currently profitable. Beone Medicines's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $915.57 million, a 1,235.63% increase year over year.
What was ONC's earnings growth in the past year?
As of Beone Medicines's earnings date in Nov 5, 2026, Beone Medicines's earnings has grown 1,140% year over year. This is 1,065.67 percentage points higher than the US Biotechnology industry earnings growth rate of 74.33%. ONC earnings in the past year totalled $915.57 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.